Featured Image

Why is it important?

Conventional phenotypic testing for pyrazinamide resistance in Mycobacterium tuberculosis is technically challenging and often unreliable. The development of a molecular assay for detecting pyrazinamide resistance would be a breakthrough, directly overcoming both the limitations of conventional testing and its related biosafety issues. Although the main mechanism of pyrazinamide resistance involves mutations inactivating the pncA enzyme, the highly diverse genetic variants scattered over the full length of the pncA gene and the lack of a reliable phenotypic gold standard hamper the development of molecular diagnostic assays. By analyzing a large number of strains collected worldwide, we have classified the different genetic variants based on their predictive value for resistance which should lead to more rapid diagnostic tests. This would assist clinicians in improving treatment regimens for patients.

Read the Original

This page is a summary of: Mycobacterium tuberculosis Pyrazinamide Resistance Determinants: a Multicenter Study, mBio, October 2014, ASM Journals,
DOI: 10.1128/mbio.01819-14.
You can read the full text:

Read

Contributors

The following have contributed to this page